BioCardia

BioCardia Debt

The Debt of BioCardia (BCDA) as of Nov 20, 2026 is 528,000.00 USD. In the previous year, Debt was 951,000.00 USD — a change of -44.48% (lower).

Debt

528,000.00USD

YoY

-44.48%

Last updated:

In 2025, BioCardia's total debt was 528,000.00 USD, a -44.48% change from the 951,000.00 USD total debt recorded in the previous year.

The BioCardia Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
124,000.00 USD
Jan 1, 2019
1.14 M USD
Jan 1, 2020
614,000.00 USD
Jan 1, 2021
1.87 M USD
Jan 1, 2022
1.63 M USD
Jan 1, 2023
1.32 M USD
Jan 1, 2024
951,000.00 USD
Jan 1, 2025
528,000.00 USD
The BioCardia Debt history
YEARDebtYoY
528,000.00USD-44.48%
951,000.00USD-27.68%
1.32 MUSD-19.37%
1.63 MUSD-12.69%
1.87 MUSD+204.23%
614,000.00USD-46.23%
1.14 MUSD+820.97%
124,000.00USD-74.06%
478,000.00USD-91.57%
5.67 MUSD-24.37%
7.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Debt Details

Understanding BioCardia's Debt Structure

BioCardia's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BioCardia's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BioCardia’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BioCardia’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BioCardia stock

Debt of BioCardia is 528,000.00 USD in 2025.

Debt of BioCardia changed from 951,000.00 USD to 528,000.00 USD, representing a -44.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt BioCardia since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioCardia

All Key Metrics — BioCardia